SkyAI (SKYA) investor relations material

Executive summary

• Completed strategic transformation, shifting from medical device operations to a technology-driven financial platform focused on agentic finance for emerging markets, leveraging AI and blockchain infrastructure, particularly Solana.

• Established international headquarters in Hong Kong to support acquisitions, talent, and expansion.

• Discontinued all R&D and manufacturing of syringe products in October 2025; now limited to sales and distribution of legacy medical devices.

Financial highlights

• Net loss of $23.3M for Q2 2026 and $109.5M for the six months ended June 30, 2026, primarily due to $84.3M unrealized and $14.7M realized losses on Solana holdings.

• Net revenue from product sales was $192,780 for the six months, up from $136,080 year-over-year.

• Staking revenue from digital assets reached $5.46M for the six months, with no comparable revenue in the prior year.

• Operating expenses rose sharply to $25.4M for the quarter, driven by higher G&A, consulting, and R&D costs.

• Cash balance at June 30, 2026 was $12.1M, with working capital of $12.6M.

Outlook and guidance

• Focused on developing an agentic finance platform for the Global South, leveraging AI and blockchain.

• Plans to finance future operations through Solana sales, equity offerings, and traditional funding until operations are self-sustaining.